Universitätsklinikum Carl Gustav Carus Dresden an der Technischen Universität Dresden Anstalt des öffentlichen Rechts des Freistaates Sachsen
Universitätsklinikum Carl Gustav Carus
ZKN Logo
  • The Center
    • Multiple Sclerosis Center Dresden
      • Patient Information
      • Contact MSC
      • Physicians & Nurses
      • Study Team
      • Neuropsychology
    • Mobility Center
      • The Mobility Center
      • Walking Assessment
      • Jump Assessment
      • DIERS
      • EMIQ
      • Projects
    • Neuroimmunological Laboratory
      • The NIL
      • Neurofilament light chain
    • Autonomic & Neuroendocrinological Functional Laboratory
      • The ANF
      • ANF Assessment
    • MS Living Lab
    • Management & Science
      • Team Management & Science
      • Projects
      • eHealth & Analytics
        • MSDS 3D
        • MSDS Clinic & Practice
        • MS-HRS
        • MTRS
      • Multiple Sclerosis Management
  • Aktuelles
    • Neuigkeiten
    • Publikationen
    • Veranstaltungen
      • Adventssymposium
      • MS Tag 2025
      • Multiple Sklerose 360°
      • Welt-MS-Tag 2021
    • Doktorarbeiten
    • Jobs
    • Kontakt
    • Spenden
  • Podcasts & Newsletter
    • Newsletter
    • Patienten-Podcast
    • Ärzte-Podcast
    • Neurovision
    • Digital calender 2026
    • Sherlock-MS-Blog
  • Studien
    • Interventionelle Studien
    • B-SHUTTLE
    • Nicht-interventionelle Studien
    • MS PATHS
    • Konectom
    • Sprachanalyse
MS 360 Grad
EnglishEnglish
DeutschDeutsch
EnglishEnglish

New insights into the pharmacokinetics and pharmacodynamics of natalizumab treatment for patients with multiple sclerosis, obtained from clinical and in vitro studies

MS Treatments

Jahr

Publikationsjahr
2016

Autoren

Autorenliste der Publikation
Sehr T, Proschmann U, Thomas K, Marggraf M, Straube E, Reichmann H, Chan A, Ziemssen T.

Verlag

Publisher-Information
J Neuroinflammation. 2016 Jun 27;13(1):164.

Link

Zur Publikation (externer Server)
https://doi.org/10.1186/s12974-016-0635-2

Tags

Forschungsthemen
Multiple SkleroseMS Behandlung
Treatments2016

  • Beyond B Cell Depletion: Adhesion and Activation Network Remodeling During Repeated Intravenous Anti-CD20 Therapy in Multiple Sclerosis

    MS Treatments
    Jahr
    2026

  • Adherence to risk minimization measures for alemtuzumab use in multiple sclerosis: a drug utilization study in four European countries

    MS Treatments
    Jahr
    2026

  • Patient profiling in relapsing multiple sclerosis: insights from a real-world observational study into the unmet medical needs of patients on disease-modifying therapy

    Multiple Sclerosis
    Jahr
    2026

  • Directions for advancing prognostic assessments in multiple sclerosis: Qualitative Insights from MS specialist Interviews

    Multiple Sclerosis
    Jahr
    2026

  • Longitudinal high-frequency blood biomarkers of axonal injury and astrocytic activation after immune reconstitution in multiple sclerosis

    NIL
    Jahr
    2025
  • Start
  • Aktuelles
  • Publikationen
  • MS Treatments
  • New insights into the pharmacokinetics and pharmacodynamics of natalizumab treatment for patients with multiple sclerosis, obtained from clinical and in vitro studies
Uniklinikum Carl Gustav Carus
UKD Neurologie
TU Dresden
Impressum & Datenschutz
MSZ @ Facebook
MSZ @ Google
ZKN @ Youtube

© 2026
Universitätsklinikum C.G. Carus Dresden an der Technischen Universität Dresden